Efficacy and safety of tyrosine kinase inhibitors in advanced hepatocellular carcinoma patients with Child-Pugh A and B cirrhosis: a meta-analysis
Frontiers in Pharmacology · 11.03.2026 · 17
DOI: 10.3389/fphar.2026.1690890 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 11.03.2026. Verfasst von Xionglin Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality. Tyrosine kinase inhibitors (TKIs) are widely used in advanced HCC, yet outcomes may differ by hepatic reserve. We compared the efficacy and safety of guideline-recommended TKIs between patients with Child–Pugh A (CP-A) and Child–Pugh B (CP-B) cirrhosis.
Methods
We conducted a PRISMA-guided systematic review and meta-analysis (searches through 15 October 2024). Eligible studies evaluated TKI monotherapy and reported outcomes separately for CP-A and CP-B. Primary endpoints were overall response rate (ORR), disease control rate (DCR), and grade ≥3 treatment-related adverse events (trAEs). Pooled risk ratios (RRs) with 95% CIs were estimated using prespecified random-effects models; small-study effects were explored with funnel plots (and Egger’s test when k ≥ 10).
Results
Twenty-four studies met inclusion. Pooled analyses showed no significant differences between CP-B and CP-A for ORR (k ≈ 15; RR 1.02, 95% CI 0.83–1.27; I 2 42.8%) and DCR (k ≈ 10; RR 0.87, 95% CI 0.58–1.29; I 2 83.1%). For grade ≥3 trAEs (k ≈ 9), CP-A had a lower risk than CP-B (CP-A vs. CP-B RR 0.79, 95% CI 0.63–1.00; I 2 61.7%), indicating a borderline increase in severe toxicity among CP-B. Funnel plots showed no clear asymmetry; Egger’s test for ORR was negative (p = 0.94), and tests were not performed for DCR and trAEs due to k < 10.
Conclusion
In advanced HCC treated with TKI monotherapy, radiologic efficacy (ORR, DCR) appears broadly comparable between CP-B and CP-A, whereas CP-B may experience higher rates of grade ≥3 toxicities. TKIs remain a reasonable option for selected CP-B patients, provided dosing is individualized and adverse events are closely monitored. Prospective, stratified studies are needed to refine patient selection and dose management in CP-B.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
- Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Ministry of Education, Nanning, China.
Zitieren
APA
Liu, X., Li, J., Li, M., & Xiang, B. (2026). Efficacy and safety of tyrosine kinase inhibitors in advanced hepatocellular carcinoma patients with Child-Pugh A and B cirrhosis: a meta-analysis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1690890
Vancouver
Liu X, Li J, Li M, Xiang B. Efficacy and safety of tyrosine kinase inhibitors in advanced hepatocellular carcinoma patients with Child-Pugh A and B cirrhosis: a meta-analysis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1690890
BibTeX
@article{Liu2026,
author = {Liu, Xionglin and Li, Jindu and Li, MinJun and Xiang, Bangde},
title = {Efficacy and safety of tyrosine kinase inhibitors in advanced hepatocellular carcinoma patients with Child-Pugh A and B cirrhosis: a meta-analysis},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1690890}
}
EUVIMED